Premium
Glucagon and a glucagon‐GLP‐1 dual‐agonist increases cardiac performance with different metabolic effects in insulin‐resistant hearts
Author(s) -
Axelsen LN,
Keung W,
Pedersen HD,
Meier E,
Riber D,
Kjølbye AL,
Petersen JS,
Proctor SD,
HolsteinRathlou NH,
Lopaschuk GD
Publication year - 2012
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.2011.01714.x
Subject(s) - glucagon , medicine , endocrinology , agonist , insulin , glycolysis , chemistry , carbohydrate metabolism , cardiac function curve , metabolism , biology , receptor , heart failure
BACKGROUND AND PURPOSE The prevalence of heart disease continues to rise, particularly in subjects with insulin resistance (IR), and improved therapies for these patients is an important challenge. In this study we evaluated cardiac function and energy metabolism in IR JCR:LA‐ cp rat hearts before and after treatment with an inotropic compound (glucagon), a glucagon‐like peptide‐1 (GLP‐1) receptor agonist (ZP131) or a glucagon‐GLP‐1 dual‐agonist (ZP2495). EXPERIMENTAL APPROACH Hearts from IR and lean JCR:LA rats were isolated and perfused in the working heart mode for measurement of cardiac function and metabolism before and after addition of vehicle, glucagon, ZP131 or ZP2495. Subsequently, cardiac levels of nucleotides and short‐chain CoA esters were measured by HPLC. KEY RESULTS Hearts from IR rats showed decreased rates of glycolysis and glucose oxidation, plus increased palmitate oxidation rates, although cardiac function and energy state (measured by ATP/AMP ratios) was normal compared with control rats. Glucagon increased glucose oxidation and glycolytic rates in control and IR hearts, but the increase was not enough to avoid AMP and ADP accumulation in IR hearts. ZP131 had no significant metabolic or functional effects in either IR or control hearts. In contrast, ZP2495 increased glucose oxidation and glycolytic rates in IR hearts to a similar extent to that of glucagon but with no concomitant accumulation of AMP or ADP. CONCLUSION AND IMPLICATIONS Whereas glucagon compromised the energetic state of IR hearts, glucagon‐GLP‐1 dual‐agonist ZP2495 appeared to preserve it. Therefore, a glucagon‐GLP‐1 dual‐agonist may be beneficial compared with glucagon alone in the treatment of severe heart failure or cardiogenic shock in subjects with IR.